Arvee Laboratories (India) Ltd.
National Stock Exchange of IndiaTotal Valuation
Arvee Laboratories (India) Ltd. carries a market capitalization of 1.80B, placing it among publicly traded companies globally. Its enterprise value stands at 2.30B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.80B |
| Enterprise Value | 2.30B |
Valuation Ratios
Arvee Laboratories (India) Ltd. trades at a trailing price-to-earnings ratio of 110.95.
| PE Ratio | 110.95 |
| PS Ratio | 8.49 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Arvee Laboratories (India) Ltd. trades at an EV/EBITDA multiple of 200.03 and an EV/FCF ratio of 1,480.18. The EV/Sales ratio of 8.49 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 200.03 provides insight into valuation relative to core operating earnings.
| EV / Sales | 8.49 |
| EV / EBITDA | 200.03 |
| EV / EBIT | 200.03 |
| EV / FCF | 1,480.18 |
Financial Position
Arvee Laboratories (India) Ltd. maintains a current ratio of 8.66, meaning it holds 8.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.60, indicating elevated leverage, while an interest coverage ratio of 9.19 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 8.66 |
| Quick Ratio | 2.29 |
| Debt / Equity | 6.60 |
| Debt / EBITDA | N/A |
| Interest Coverage | 9.19 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Return on Invested Capital (ROIC) | 5.59 |
| Return on Capital Employed (ROCE) | -2.51 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Arvee Laboratories (India) Ltd. has paid -4.05M in income taxes, reflecting an effective tax rate of 31.07.
| Income Tax | -4.05M |
| Effective Tax Rate | 31.07 |
Stock Price Statistics
Arvee Laboratories (India) Ltd.'s stock has declined approximately -13.13458% over the past 52 weeks. The 50-day moving average sits at 164.41, while the 200-day moving average is 168.57.
| Beta (5Y) | N/A |
| 52-Week Price Change | -13.13458% |
| 50-Day Moving Average | 164.41 |
| 200-Day Moving Average | 168.57 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Arvee Laboratories (India) Ltd. generated 271.11M in revenue and converted that into 20.75M in net income, yielding earnings per share of 1.92. EBITDA reached 11.51M, while operating income came in at 11.51M.
| Revenue | 271.11M |
| Gross Profit | 122.13M |
| Operating Income | 11.51M |
| Pretax Income | 16.70M |
| Net Income | 20.75M |
| EBITDA | 11.51M |
| EBIT | 11.51M |
| Earnings Per Share (EPS) | 1.92 |
Margins
Arvee Laboratories (India) Ltd. operates with a gross margin of 45.05, reflecting its pricing power and cost economics. The operating margin of 4.25 and net profit margin of 7.65 provide insight into operational efficiency.
| Gross Margin | 45.05 |
| Operating Margin | 4.25 |
| Pretax Margin | 6.16 |
| Profit Margin | 7.65 |
| EBITDA Margin | 4.25 |
Stock Splits
Arvee Laboratories (India) Ltd.'s most recent stock split took place on October 13, 2020 with a 1:2 split ratio.
| Last Split Date | 10/13/2020 |
| Split Ratio | 1:2 |
Scores
Arvee Laboratories (India) Ltd. posts an Altman Z-Score of 13.84, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 13.84 |